This module uses fundamental data of Jinhe Biotechnology to approximate the value of its Beneish M Score. Jinhe Biotechnology M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jinhe Biotechnology Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Jinhe
Beneish M Score
Other Cashflows From Financing Activities
Dividends Paid
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
Change To Account Receivables
Change To Inventory
Other Cashflows From Investing Activities
Investments
Change In Cash
Net Borrowings
Total Cashflows From Investing Activities
Depreciation
Change To Operating Activities
Change To Netincome
Change To Liabilities
End Period Cash Flow
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Non Cash Items
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Short Term Debt
Intangible Assets
Common Stock
Other Liab
Other Assets
Property Plant Equipment
Long Term Debt
Good Will
Net Tangible Assets
Deferred Long Term Liab
Long Term Investments
Short Long Term Debt
Short Term Investments
Non Current Liabilities Other
Net Invested Capital
Net Working Capital
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Interest Expense
Selling General Administrative
Total Revenue
Operating Income
Cost Of Revenue
Income Before Tax
Net Income Applicable To Common Shares
Income Tax Expense
Minority Interest
Research Development
Gross Profit
Other Operating Expenses
Net Income From Continuing Ops
Ebit
Total Operating Expenses
Total Other Income Expense Net
Tax Provision
Net Interest Income
Interest Income
Ebitda
Reconciled Depreciation
Probability Of Bankruptcy
At present, Jinhe Biotechnology's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Net Debt is expected to grow to about 1.8 B, whereas Long Term Debt is forecasted to decline to about 262.5 M.
At this time, Jinhe Biotechnology's M Score is inapplicable. The earnings manipulation may begin if Jinhe Biotechnology's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Jinhe Biotechnology executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Jinhe Biotechnology's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Jinhe Biotechnology's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Jinhe Biotechnology's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Jinhe Biotechnology in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Jinhe Biotechnology's degree of accounting gimmicks and manipulations.
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Reconciled Depreciation
132.85 Million
At present, Jinhe Biotechnology's Reconciled Depreciation is projected to increase significantly based on the last few years of reporting.
Jinhe Biotechnology Earnings Manipulation Drivers
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Jinhe Biotechnology. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
The Macroaxis Fundamental Analysis modules help investors analyze Jinhe Biotechnology Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jinhe Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jinhe Biotechnology Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Jinhe Biotechnology financial ratios help investors to determine whether Jinhe Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jinhe with respect to the benefits of owning Jinhe Biotechnology security.